Phase 2b trial of an oral relaxin family peptide receptor 1 agonist in patients with chronic heart failure: rationale and design

What Was Tested

This randomized controlled trial paper looks at Relaxin (Serelaxin).

Who Took Part

According to the abstract, 360 participants were involved.

The age groups tagged for this paper are middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Relaxin (Serelaxin) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Relaxin (Serelaxin), so expectations could not easily colour the readings.

Some participants received a placebo instead of Relaxin (Serelaxin), giving a reference point.

The methods mention a period of 24 weeks.

Primary endpoints are changes in end-systolic volume index (Cohort A) and systemic vascular resistance index (Cohort B) after 24 weeks.

The safety of AZD5462 will be monitored throughout the study.

What Was Measured

The subject headings attached to it are Heart Failure, Stroke Volume, Chronic Disease, Ventricular Function, Left, Relaxin, Echocardiography and Receptors, Peptide.

The authors tagged it with the keywords End-systolic volume index (ESVI), Phase 2 trial, RXFP1 agonist and Systemic vascular resistance index (SVRI).

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Relaxin (Serelaxin) in 360 participants over 24 weeks.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 2 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (ESC heart failure), a journal based in England.

More context: the Relaxin (Serelaxin) compound page, all human trials.